INDICATION: QUZYTTIR is indicated for the treatment of acute urticaria in adults and children 6 months of age and older.
Why QUZYTTIR may be a good option for your patients
QUZYTTIR's efficacy in reducing pruritis was demonstrated in a phase 3, non-inferiority study comparing QUZYTTIR to intravenous diphenhydramine (IV DPH) as an active control.1
- * Mean time spent in the ED or clinic (from administration to readiness for discharge) was 1.7 hours with QUZYTTIR vs 2.1 hours with IV DPH. The proportion of patients returning to any ED or clinic within 48 hours post-discharge was 6% with QUZYTTIR vs 14% with IV DPH.1,2
- † Less sedation at all time points (1 hour, 2 hours, and discharge) in the phase 3 trial.
- ‡ In a single-dose crossover study in healthy volunteers, QUZYTTIR 5 mg and 10 mg reached a mean Cmax of 495 ng/mL and 1344 ng/mL, with time to Cmax of 3.6 minutes and 1.8 minutes, respectively.
